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Research
AbstrACt
Objectives To undertake an economic analysis 
assessing the cost-effectiveness of a single dose of oral 
dexamethasone compared with placebo for the relief of 
sore throat.
Design A UK-based, multicentre, two arm, individually 
randomised, double blind trial.
setting and population Adults (≥18 years) with 
acute sore throat and painful swallowing judged to 
be infective in origin, recruited and randomised in 
primary care. Intervention: a single dose of 10 mg 
oral dexamethasone compared with placebo given at 
primary care visit.
Main outcome Incremental cost-effectiveness 
ratios (ICERs), cost per quality-adjusted symptom 
resolution using the EuroQol-five dimensions-five levels 
instrument, were estimated as part of a cost–utility 
analysis performed on an intention-to-treat cohort 
adopting a health payers perspective.
results Differences in health-related quality of life 
(HRQoL) over 7 days from baseline and at 24 hours in 
the dexamethasone compared with the placebo group 
(2.9% and 2.5% higher, respectively) were observed. 
After controlling for the baseline HRQoL imbalances, 
the economic impact of the intervention was not 
statistically significant: the quality-adjusted life year 
difference was −0.00005 (95% CI −0.0002 to 0.00011) 
equivalent to a loss in HRQoL of a half hour in the 
dexamethasone group. The average cost per patient 
associated in the dexamethasone and placebo groups 
in the basecase analysis was £73 and £69, respectively. 
In the basecase probabilistic analysis, the mean ICER 
was −£6440 (95% CI −£132 151 to £126 335) and 
the median ICER was −£304 (IQR-£5816 to £3877); 
suggesting considerable uncertainty.
Conclusions and relevance The economic burden 
associated with sore throat is substantial and was 
estimated at £2.35 billion to the healthcare services 
payer based on reported resource use and 2015 UK 
unit costs. There is considerable uncertainty regarding 
the cost-effectiveness of a single dose of oral 
dexamethasone as a treatment strategy and therefore 
insufficient evidence to support its use in clinical 
practice.
trial registration number ISRCTN17435450; Post-
results.
IntrODuCtIOn 
An estimated £400 million annually is spent 
on consultations and lost productivity asso-
ciated with sore throat alone in the UK.1 2 
Almost 1 in 10 registered UK patients will see 
their general practitioner (GP) every year 
with sore throat.3 Ninety-one per cent of those 
diagnosed with tonsillitis will receive antibi-
otics, as will half of those recorded as ‘sore 
throat’ or ‘pharyngitis’.4 National Institute 
for Health and Care Excellence (NICE) and 
International guidance recognises the limited 
evidence for benefit of antibiotics in its advice 
to avoid prescriptions in the majority of 
patients5 6; however, prescribing rates remain 
disproportionately high even though patients 
attend mainly due to anxiety over symptoms.7 
A key driver for patients to attend with a sore 
strengths and limitations of this study
 ► The analysis undertaken provides the first detailed 
account of the cost of sore throat in the UK.
 ► The study collected a wide range of demographic, 
clinical, quality of life and resource use data using a 
trial-specific daily patient diary which permitted an 
extensive exploration of uncertainty in scenario and 
subgroup analyses.
 ► Both health services payer and societal perspectives 
were assessed in the economic evaluation.
 ► In contrast to previous research highlighting no 
clinical differences across delayed prescription and 
no treatment strategies, this analysis suggests that 
clinical and non-clinical benefits of the delayed pre-
scription in addition to the dexamethasone need to 
be explored further.
 ► Reported resource use for healthcare services pay-
er perspective analysis was cross-checked with a 
follow-up patient survey and medical record review 
and as such where no resource use was identi-
fied for each patient across the data sources, the 
assumption of zero resource use for that category 
is justifiable but potentially leading to some bias in 
cost estimates.
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throat is the severity of their symptoms, so affective symp-
tomatic treatment may help reduce patient reliance on 
antibiotic. Furthermore where antibiotics are used for 
streptococcal infections more rapid clinical improve-
ment is also plausible with steroids,8 which could facili-
tate shorter courses of antibiotics, which would improve 
both prescribing and the overall economic burden of 
sore throat. Further, negative externalities associated with 
overprescribing antibiotics, predominantly the increasing 
issue of antimicrobial resistance9 could also be moder-
ated. The Treatment Options without Antibiotics for Sore 
Throat (TOAST) trial10 addressed whether or not oral 
corticosteroids provide clinical and cost-effective benefits 
through symptom relief of sore throat. The findings of 
the trial highlighted no clinical impact of a single dose of 
oral dexamethasone compared with placebo for resolu-
tion of symptoms at 24 hours; however, at 48 hours there 
was a significant improvement for patients receiving 
the intervention.11 The cost-effectiveness analysis along-
side the TOAST trial assessed the costs and benefits of a 
single dose of 10 mg oral dexamethasone compared with 
placebo for the symptom relief of sore throat.
MethODs
Intervention
TOAST was a multicentre, two-arm, individually 
randomised, double blind trial comparing a single dose 
of 10 mg oral dexamethasone with identical placebo in 
adults aged between 18 and 70 years1 inclusive, presenting 
to primary care with acute sore throat. Recruitment took 
place in 42 primary care clinics in England from April 
2013 to February 2015. The intervention period assessed 
was 7 days postpresentation and participants were 
followed up for 28 days to assess resource use and adverse 
events. A subgroup of patients in each trial arm received 
a delayed prescription for antibiotics at the discretion of 
the GP and randomisation was stratified by this decision. 
Further details on trial design are published elsewhere. 6
Outcome measure
The cost-effectiveness analysis assessed quality-adjusted 
symptom resolution over the 7-day trial duration and 
estimated median time to complete resolution of symp-
toms and the corresponding utility gains measured by the 
EuroQol-five dimensions-five levels (EQ-5D-5L) index. 
These outcomes informed the construction of a quali-
ty-adjusted life year (QALY) used in the cost–utility anal-
ysis. The EuroQol instrument has five domains (mobility, 
self-care, activities, pain/discomfort and anxiety/depres-
sion) and five response levels ranging from no problems 
to severe problem.12 This health-related quality of life 
(HRQoL) instrument was administered to all partic-
ipants at baseline and completed on each day of the 
7-day patient diary. Each of the five dimensions in the 
EQ-5D-5L version is scored from 1 (no problem) to 5 
(extreme problems), generating a profile (eg, 11 245) 
that can be used to calculate a single index score (range 
−0.281 to 1.000).13 The EQ-5D instrument also generates 
a self-rating of HRQoL scored from 0 to 100 employing a 
Visual Analogue Scale; this was used in scenario analyses. 
Quality-adjusted symptom resolution at 24 and 48 hours 
were also reported.
resource use
Primary care resource utilisation was recorded in a 
trial patient diary for the first 7 days of the trial and 
was complemented by a follow-up survey sent to those 
with incomplete patient diaries. A primary care patient 
medical record review for the period from day 1 to day 
28 (trial follow-up period) was also undertaken which 
recorded primary and secondary care contacts related 
to sore throat including serious adverse events (SAEs) 
related to the condition. SAEs included in the analysis 
were those classified as such by the trial protocol; and 
detailed in the main trial paper.11 Resource use included 
the following: visits and telephone calls to the GP; visits 
and telephone calls to nurses; out-of-hours calls and visits; 
pharmacy visits; calls to helpline ‘111’; accident and emer-
gency (A&E) visits; hospitalisations and various types of 
reported medication including prescribed antimicrobials 
and over-the-counter (OTC) medications.
unit costs
Total and average costs were estimated for the inter-
vention, antibiotic usage (up to and including day 7), 
OTC medication usage (for days 0–7), health resource 
use/medication across the trial period (for days 1–28), 
SAEs and patient productivity losses associated with sick 
days reported (for work and education) and inability to 
carry out usual activities. Unit costs, presented in the 
(online supplementary file 1), were obtained from a 
number of sources including, Personal Social Services 
Research Unit (PSSRU),14 British National Formulary,15 
Boots Chemist16 and the National Health Service Elec-
tronic Tariff Database17 and are reported in UK currency. 
Productivity losses were costed using average wage rates for 
those employed and minimum wage rates for students.18 
All cost estimates were reported in 2015 GBP using appro-
priate adjustments for prices retrieved where necessary.19 
Disaggregated average cost estimates reported were based 
on the full cohort in the intention-to-treat (ITT) analysis 
assuming non-responders had zero costs.
Analysis
Patient characteristics and reported resource use were 
summarised by trial arm. The primary economic analysis 
was conducted on an ITT basis and adopted the health-
care services payer perspective (HSP) which included 
the cost burden to the HSP only. Given the short-term 
duration of the trial, neither costs nor benefits were 
discounted. For the HSP the prescription administra-
tive charge, normally applied to employed, working-age 
adults only in the UK,20 associated with the antimicro-
bial was not incorporated into the cost analysis as this 
was considered an out-of-pocket (OOP) expense borne 
 o
n
 1 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019184 on 28 April 2018. Downloaded from 
3Burns RM, et al. BMJ Open 2018;8:e019184. doi:10.1136/bmjopen-2017-019184
Open Access
by the patient; this was not considered as a contribution 
to the HSP either, that is, reducing the net cost of care 
per person to the HSP, as the prescription administrative 
charge is not applied to everyone and the full amount 
may not be recouped by the HSP.21 In the scenario anal-
yses, a societal costing perspective (SCP) was also adopted 
reflecting the overall economic burden of the dexameth-
asone relative to the placebo. This included productivity 
losses due to sick days, that is, reported time off due to 
missed work or education and reported inability to carry 
out usual activities, and OOP expenses. Further scenarios 
assessed subgroups based on patient characteristics. The 
subgroup who highlighted they were current smokers at 
the time of the trial were assessed in a scenario analysis 
due to the extra healthcare burden smokers have rela-
tive to non-smokers.22 Descriptions of all 20 analyses are 
presented in the (online supplementary table A2).
Each element of costs and outcomes was reported sepa-
rately, consistent with a cost–consequence analysis; the 
resource use reported was for the full ITT cohort (ie, no 
missing resource use data) and the HRQoL data reported 
in the disaggregated format was for complete cases, that 
is, n=337; 60% of the full cohort. Missing HRQoL data 
were assessed and classified as missing at random (see 
online supplementary appendix figure A1).16 Multiple 
imputation analysis was performed for missing outcome 
data (40%) in the ITT cohort using a number of impu-
tations (n=60) greater than the proportion of missing 
data.23 The range of covariates included in the multiple 
imputation analysis along with a more comprehensive 
presentation of methods is presented (see online supple-
mentary appendix table A3). The trial and follow-up 
duration was 28 days in total and for consistency it was 
assumed that HRQoL was unchanged from day 7 to day 
28 using the last value brought forward technique.24 
The average utility from baseline reported across the 28 
days, calculated using area under the curve was consid-
ered 1/13th of a QALY. Baseline variation in outcomes 
was adjusted for incorporating multiple regression and 
seemingly unrelated regression techniques which esti-
mated the baseline imbalance taking into account costs 
and effects.16 25 QALYs exhibited a non-normal distribu-
tion (see online supplementary appendix tables A4–A5) 
and bootstrapping techniques using 1000 iterations were 
applied in Microsoft Excel.26 The differences in EQ-5D-5L 
from baseline (day 0) at each day, that is, days 1–7 were 
estimated and results from the complete case analysis 
(n=337) and the ITT analysis (n=565) are presented in 
the (online supplementary appendix tables A4–A5). Cost–
utility analysis was undertaken and incremental cost-ef-
fectiveness ratios (ICERs) were estimated and reported 
for the basecase analysis and all scenario analyses. ICERs 
were probabilistic for the basecase analysis and determin-
istic for the series of scenarios estimated. The analysis was 
undertaken in Stata V.14.1.27 A cost-effectiveness plane 
and cost-effectiveness acceptability curve (CEAC) were 
constructed based on the bootstrapped sample means 
and net monetary benefit (NMB) was also assessed against 
a range of willingness to pay thresholds up to £100 000.28 
NICE willingness to pay threshold of £20 000 was adopted 
as a decision rule to assess cost-effectiveness.27
results
The ITT cohort (n=565) had 288 in the dexamethasone 
group and 277 in the placebo group; descriptive statistics 
are presented in table 1. The mean age of participants was 
37 years and 75% were women. There was no significant 
clinical difference in median time to complete symptom 
resolution across trial arms with both displaying complete 
symptom resolution by day 4; however, there was a signif-
icant difference in symptom resolution at 48 hours.11 The 
changes in HRQoL over the 7 days highlight larger differ-
ences at baseline and at 24 hours with the dexamethasone 
group reporting 2.9% and 2.5% higher utility scores, 
respectively (see online supplementary appendix figures 
A3–A4). Differences start to diminish (<1.5%) from day 2 
onwards. Table 2 highlights the differences in estimated 
QALYs for the imputed ITT cohort. After controlling 
for the baseline imbalances in HRQoL, the impact of 
the intervention was negative but not statistically signif-
icant: the QALY gain was −0.00005 (95% CI −0.0002 to 
0.00011) equivalent to a loss in HRQoL of a half hour for 
the dexamethasone relative to the placebo group. Unad-
justed differences in HRQoL for the ITT and complete 
case cohorts are presented (see online supplementary 
appendix figures A4–A5).
For the subgroup who received the delayed prescrip-
tion based on clinical need, a statistically significant 
benefit was evidenced after baseline imbalances were 
adjusted for resulting in an approximate HRQoL gain of 
13.6 hours relative to the control group. For the subgroup 
who did not receive the prescription, the dexamethasone 
group indicated a significant QALY loss of approximately 
13 hours relative to the placebo group. For the patient 
group who reported that they were current smokers a 
significant QALY gain from the dexamethasone of 0.0029, 
equivalent to 1 day was evidenced. At 48 hours where a 
significant difference in the risk ratio of symptom reso-
lution at 48 hours in favour of the dexamethasone (RR 
1.31 (95% C, 1.02 to 1.68; p=0.03)) was observed, the 
significant QALY gain approximated to 3.7 hours for the 
current smokers subgroup.
The average cost per patient associated with the dexa-
methasone and placebo groups in the basecase analysis 
adopting a HSP was £73 and £69, respectively. Table 3 
highlights total costs for the categories included in the 
economic evaluation. Average costs were higher across 
both trial arms for the subgroup who did not receive the 
delayed prescription relative to the subgroup who did 
(£24 and £18 higher in the placebo and dexamethasone 
groups, respectively) driven by higher health service utili-
sation; however, no statistically significant impact on costs 
across these subgroups for the HSP was found. For the 
SCP, including the cost associated with inability to carry 
out usual activities (Scenario I), the average cost per 
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patient was £126 and £134 for the dexamethasone and 
placebo groups, respectively. This suggests a cost saving of 
£7 per patient to society. For the subgroup who received 
the delayed prescription, there was a negligible SCP reduc-
tion in the dexamethasone group of −£0.18; however, 
for those who did not receive the delayed prescription 
the SCP reduction for the substantial at −£12 signalling 
strong evidence of cost savings from the use of oral dexa-
methasone compared with placebo.
In the deterministic basecase analysis (table 4), the 
ICER was negative at −£81 400 due to the size and sign 
of the incremental effectiveness. In the basecase prob-
abilistic analysis, the mean ICER was −£6440 (95% CI 
−£132 151 to £126 335) and the median ICER was −£304 
(IQR: −£5816 to £3877); suggesting there is consider-
able uncertainty around this estimate. Several societal 
scenarios highlighted the potential for cost savings; 
however, due to outcome variability, there is insufficient 
evidence to suggest the dexamethasone is cost-effective. 
The cost-effectiveness plane (figure 1) presents a visual 
representation of the spread of the variation in cost 
and effect pairs for the basecase probabilistic analysis 
Table 1 TOAST trial patient characteristics
Placebo
group
Dexamethasone
group
All eligible participants (ITT) 277 (49%) 288 (51%)
  Male 73 (13%) 67 (12%)
  Female 204 (36%) 221 (39%)
  Mean age* 37.3 (SD: 14.30) 37.2 (SD: 14.36)
  Current smoker 51 (9%) 52 (9%)
Antibiotic details† 
  Given delayed prescription 108 (19%) 115 (20%)
  Reported taking antibiotics 42 (7%) 34 (6%)
  Not given delayed prescription 169 (30%) 173 (31%)
  Reported taking antibiotics 16 (3%) 16 (3%)
  Total reported antibiotics usage 58 (10%) 50 (9%)
Resource use
  Reported using OTC medicines (days 1–7) 178 (32%) 173 (31%)
  Reported resource use (days 1–7) 69 (12%) 67 (12%)
  Reported resource use in follow-up (days 8–28) 20 (4%) 30 (5%)
  SAE‡ 1 (<1%) 1 (<1%)
  Other AE 1 (<1%) 0 (0%)
Employment status/sick days
  Reported working FT (22 years and over) 149 (26%) 145 (26%)
  Reported working PT (22 years and over) 40 (7%) 39 (7%)
  Assumed in FT/PT education§ (18–21 years) 28 (5%) 33 (6%)
  Unemployed 60 (11%) 71 (13%)
  Sick days—proportion reporting >1 hour missing (days 0–7) 104 (18%) 89 (16%)
  Sick days—proportion reporting >1 hour missing (days 1–7) 72 (13%) 60 (11%)
  Usual activities—proportion reporting >1 hour missing (days 0–7) 137 (24%) 127 (22%)
  Usual activities—proportion reporting >1 hour missing (days 1–7) 98 (17%) 104 (18%)
Percentages in brackets represent proportion of full trial cohort (n=565). 
*Mean age was estimated using the ITT population previous to the amendment to inclusion criteria constricting the upper age limit to 70 
years. Fourteen patients were over 70 years evenly distributed across both arms.
†Antibiotics reported for ‘sore throat’ are included if prescribed within the 7-day trial period and were administered outside a secondary care 
setting. This deviates slightly from the clinical paper analysis classification of overall antibiotic use which included antibiotics administered in 
secondary care for one patient in the control group.
‡SAE’s included were categorised as ‘Suspected Serious Adverse Reaction’ in the clinical paper. Although three such events were reported, 
one was linked to a further SAE ultimately resulting in death and so was excluded from the economic analysis.
§Those aged 18–21 years reporting ‘yes’ to FT/PT work/education question in the baseline survey were all categorised into education for 
purposes of costing productivity losses in a scenario (see online supplementary appendix).
AE, adverse event; FT/PT, full time/part time; ITT, intention-to-treat; OTC, over-the-counter; SAE, serious adverse event; TOAST, Treatment 
Options without Antibiotics for Sore Throat. 
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emphasising the wide variation in effectiveness. Due to 
this uncertainty, the CEAC (see online supplementary 
appendix figure A5) suggests the probability of cost-effec-
tiveness is 47.9% at a £20 000 willingness to pay threshold. 
The mean NMB was £1.80 (SD: £351) at a £20 000 will-
ingness to pay threshold with a 43.5% probability of the 
dexamethasone yielding a net benefit.
DIsCussIOn
The analysis undertaken provides the first detailed 
account of the cost of sore throat in the UK estimating 
that on average, costs of treating sore throat to the HSP 
are approximately £69 per patient and to society £134. 
With approximately 340 million consultations annually in 
the UK29 and 1 in 10 due to sore throat,4 the economic 
burden is estimated at £2.35 billion (or £4.56 billion to 
society) based on UK unit costs. The average cost differ-
ence was £4.07 (higher in the dexamethasone group): 
the dexamethasone group cost differential was £5.04, 
that is, the cost to the HSP of the single dose of oral dexa-
methasone. Therefore, from the HSP, there is insufficient 
evidence to suggest the intervention is cost-effective and 
there is some evidence to suggest the intervention may be 
producing a negative impact on HRQoL across the whole 
cohort.
strengths and limitations of the study
The study collected a wide range of demographic, clin-
ical, QoL and resource use data using a trial-specific 
daily patient diary which permitted an extensive explo-
ration of uncertainty in scenario and subgroup analyses. 
Subgroup analysis indicated that for those who received 
the delayed antibiotic prescription and the dexameth-
asone versus those who received the delayed prescrip-
tion and the placebo, the effect on HRQoL was positive 
and significant and therefore the resulting ICERs were 
cost-effective at £4950 per QALY gain. In contrast the 
placebo subgroup not given the delayed prescription 
had a significantly negative effect. GPs selected patients 
who were perceived to be in greater clinical need for the 
delayed prescription sub-arm of the trial; as this subgroup 
may have had increased severity of symptoms relative 
to their counterparts, they had more scope to improve 
from a clinical and HRQoL perspective which in part 
may explain the variation in HRQoL for the subgroups. 
Additionally, the average costs of those in the ‘no delayed 
prescription’ subgroup who received intervention or 
placebo were 30% and 45% times higher, respectively, 
than those in the comparative subgroup who received the 
delayed prescription. Cost differences observed across 
subgroups were primarily driven by higher reported 
health service use contacts across the trial and follow-up 
periods: 210% increase in the ‘no delayed prescription’ 
subgroups overall and 157% and 286% higher for the 
intervention and placebo arms, respectively. Caution 
is needed in interpreting this variation as the trial was 
not powered for subgroup analysis of resource use and 
response rates were low. Previous research did not find 
Table 2 Quality-adjusted life year (QALY) analysis
Placebo (n=277*)
Mean (SE)
Dexamethasone (n=288*)
Mean (SE)
Difference (Dexamethasone 
-placebo) P values
Imputed unadjusted QALYS 0.07165 (0.0006) 0.07199 (0.0005) 0.00034 (0.0009) <0.000
Imputed QALYs, adjusted for baseline 
differences
0.07672 (0.0004) 0.07677 (0.0005) −0.00005 (0.00008) 0.522
Imputed QALYs for those given delayed 
prescription (adjusted)
0.0743 (0.0005) 0.0759 (0.0006) 0.00155 (0.0001) <0.000
Imputed QALYs for those not given a 
delayed prescription (adjusted)
0.0785 (0.0005) 0.0770 (0.0007) −0.00149 (0.0001) <0.000
Imputed QALYs with patients removed 
who experienced SAE or AE (adjusted) 
(n=562)
0.0768 (0.0004) 0.0767 (0.0005) −0.00006 (0.00008) 0.473
Imputed QALYs with patients removed 
who were over 70 years (adjusted) 
(n=551)
0.0766 (0.0004) 0.0765 (0.0005) −0.000123 (0.00008) 0.128
Imputed QALYs with patients who were 
current smokers only (adjusted) (n=103)
0.0738 (0.0008) 0.0768 (0.0010) 0.00294 (0.00018) <0.000
Imputed QALYs at 24 hours, adjusted for 
baseline differences
0.00270 (0.000008) 0.00271 (0.000010) 0.00001 (0.000002) <0.000
Imputed QALYs at 48 hours, adjusted for 
baseline differences in HRQoL
0.00535 (0.000025) 0.00538 (0.000031) 0.00003 (0.000005) <0.000
Imputed QALYs at 48 hours, adjusted for 
baseline differences in HRQoL and RR of 
symptom resolution
0.00492 (0.000024) 0.00534 (0.000029) 0.000422 (0.000005) <0.000
*This sample size is based on 60 imputed datasets.
AE, adverse event; HRQoL, health-related quality of life; RR, relative risk; SAE, serious adverse event. 
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Table 3 Cost analysis
Cost bundle category Description
Total cost 2015 £ Average cost 2015 £
Placebo 
Dexa-
methasone 
(Dex-
placebo) Placebo 
Dexa- 
methasone 
(Dex- 
placebo) 
Intervention Cost associated with the intervention. £12 188 £14 124 £1936 £44 £49.04 £5.04
Antibiotics—cohort A Cost associated with antibiotics reported in patient 
survey, follow-up survey and medical records.
£164 £138 −£26 £0.59 £0.48 −£0.11
Antibiotics—cohort B Cost associated with antibiotics reported in patient 
survey and medical records only.
£154 £128 −£26 £0.55 £0.44 −£0.11
Antibiotics—societal Cost associated with antibiotics inclusive of the 
patient copayment for prescriptions.
£689 £581 −£108 £2.49 £2.02 −£0.47
Antibiotics B—societal Cost associated with antibiotics inclusive of the 
patient copayment for prescriptions for cohort B.
£646 £538 −£108 £2.33 £1.87 −£0.46
Antibiotics—societal for 
workers
Cost associated with antibiotics inclusive of the 
patient copayment for prescriptions for workers only.
£623 £474 −£149 £2.25 £1.65 −£0.60
Antibiotics B—societal for 
workers
Cost associated with antibiotics inclusive of the 
patient copayment for prescriptions for workers only 
in cohort B.
£547 £431 −£116 £1.98 £1.50 −£0.48
Over-the-counter (OTC) Cost associated with reported OTC in the patient diary 
and follow-up survey.
£668 £648 −£20 £2.41 £2.25 −£0.16
Resource use—patient diary Cost associated with resource use reported in the 
patient diary.
£2639 £2732 £93 £9.53 £9.49 −£0.04
Resource use—follow-up 
survey
Cost associated with resource use reported in the 
follow-up survey.
£4082 £4008 −£74 £14.74 £13.92 −£0.82
Productivity losses—days 0–7 
and follow-up
Cost of missed days due to illness reported in the 
patient diary and follow-up survey.
£22 668 £19 469 −£3199 £81.83 £67.60 −£14.23
Productivity losses (B)—days 
0–7 and follow-up
Cost of missed days due to illness assuming all 
18–21 year olds were in education.
£21 505 £18 634 −£2871 £77.63 £64.70 −£12.93
Productivity losses—days 1–7 
and follow-up
Cost of missed days due to illness reported in the 
patient diary from day 1 and follow-up survey.
£14 846 £12 699 −£2147 £53.59 £44.09 −£9.50
Productivity losses (B)—days 
1–7 and follow-up
Cost of missed days due to illness (from day 1) 
assuming all 18–21 year olds were in education.
£14 176 £12 140 −£2036 £51.17 £42.15 −£9.02
Usual activities—days 0–7 and 
follow-up
Cost associated with missing time due to illness 
for usual activities reported in the patient dairy and 
follow-up survey.
£4904 £5052 £148 £17.70 £17.54 −£0.16
Usual activities—days 1–7 and 
follow-up
Cost associated with missing time due to illness (from 
day 1) for usual activities reported in the patient dairy 
and follow-up survey.
£3444 £3672 £228 £12.43 £12.75 £0.32
Total HSP costs—primary 
analysis
£19 073 £21 002 £1929 £68.86 £72.92 £4.07
Total HSP costs—without 
SAE’s/AEs (n=562)
option (A)
£15 610 £18 349 £2739 £56.76 £63.93 £7.17
Total HSP costs—
delayed prescription
£5830 £7119.00 £1289 £53.99 £61.90 £7.91
Total HSP costs—
no delayed prescription
£13 243 £13 883 £640 £78.36 £80.25 £1.89
Total HSP costs—
smokers only
(n=103)
£6059 £2787 −£3272 £118.81 £53.60 −£65.21
Total SCP
option (I)
£37 076 £36 409 −£667 £133.85 £126.42 −£7.43
Total SCP without SAE’s/AEs 
(n=562)
£33 012 £33 726 −£667 £120.04 £117.51 −£2.53
Total SCP—
delayed prescription
£12 995 £13 816 £821 £120.32 £120.14 −£0.18
Total SCP—
no delayed prescription
£24 081 £22 593 −£1488 £142.49 £130.59 −£11.90
Total SCP—
smokers only (n=103)
£8739 £3259 −£5480 £171.35 £62.68 −£108.67
Cohort A has an additional eight patients included who reported antibiotic use in follow-up surveys only. Cohort B does not include these patients in keeping with 
the statistical analysis plan outlined for the clinical analysis.
AEs, adverse events; HSP, healthcare services payer perspective; SAE’s, serious adverse events; SCP, societal costing perspective. 
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any clinical differences across delayed prescription and 
no treatment strategies30; however, our findings suggest 
that the clinical and non-clinical benefits of the delayed 
prescription in addition to the dexamethasone need to 
be explored further.
Although only a slight reduction in antibiotic usage was 
observed in the intervention arm relative to the placebo, 
that is, 3% less reported use for the delayed prescription 
subgroup, we feel the range of budgetary, clinical and 
environmental benefits of reducing antibiotic usage need 
to be explored further given the evidence highlighted in 
this study.
When assessing the impact of the dexamethasone on 
those who reported being current smokers (n=103, equally 
distributed between trial arms), there was a significant 
increase in HRQoL from baseline suggestive of cost-effec-
tiveness for smokers: ICER £6533. Due to higher risk of 
prolonged symptoms compared with previous smokers or 
non-smokers, this intervention may provide an interactive 
anti-inflammatory perhaps akin to effects in patients with 
exacerbations of chronic obstructive pulmonary disease, 
primarily caused by smoking.
Adoption of a SCP highlighted cost savings for the inter-
vention relative to the control group. The main driver of 
difference in the range of scenarios adopting a SCP was 
the cost associated with missing work or education due to 
sickness. However, there were also differences in reported 
OTC medication usage across trial arms and subgroups 
that may influence recovery.
The study is not without its limitations. Missing data 
were an issue as the main tool for data collection was a 
patient completed diary at each day of the trial follow-up: 
HRQoL over the 7 days was 60% complete and the 
resource use reported in diaries was 62% complete. 
Table 4 Cost–utility analysis (deterministic models)
Scenarios* Control Intervention ∆ in cost ∆ in effect† ICER Interpretation‡
Healthcare services payer perspective
  Basecase £68.86 £72.92 £4.07 −0.00005 −£81 400 Not cost-effective
  Scenario A £56.76 £63.93 £7.17 −0.00010 −£71 700 Not cost-effective
  Scenario B £69.22 £73.37 £4.15 −0.00012 −£33 850 Not cost-effective
  Scenario C £53.99 £61.90 £7.92 0.00160 £4950 Cost-effective
  Scenario D £78.36 £80.25 £1.89 −0.0015 −£1260 Not cost-effective
  Scenario E £57.58 £77.18 £19.60 0.0030 £6533 Cost-effective
  Scenario F £68.86 £72.92 £4.07 0.00001 £407 000 Not cost-effective
  Scenario G £68.86 £72.92 £4.07 0.00042 £9690 Cost-effective
  Scenario H§ £68.86 £72.92 £4.07 −0.0038 −£1071 Not cost-effective
Societal cost perspective
  Scenario I £133.85 £126.42 −£7.43 −0.00005 £1 48 600 Not cost-effective
  Scenario J £167.36 154.72 −£12.64 −0.00005 £2 52 800 Not cost-effective
  Scenario K £120.04 £117.51 −£2.53 −0.00010 £25 300 Not cost-effective
  Scenario L £135.51 £127.59 −£7.92 −0.00005 £158 400 Not cost-effective
  Scenario M £135.23 £127.44 −£7.79 −0.00005 £155 800 Not cost-effective
  Scenario N £120.32 £120.14 −£0.18 0.00160 −£112 Cost-effective and cost saving
  Scenario O £142.49 £130.59 −£11.90 −0.00150 £7933 Not cost-effective
  Scenario P £171.35 £62.68 −£108.67 0.0030 −£36 223 Cost-effective and cost saving
  Scenario Q £133.85 £126.42 −£7.43 0.00001 −£743 000 Cost-effective and cost saving
  Scenario R £133.85 £126.42 −£7.43 0.00042 −£17 690 Cost-effective and cost saving
  Scenario S§ £133.85 £126.42 −£7.43 −0.0038 £1955 Not cost-effective
*Full scenario details are presented in the (online supplementary file 1).
†Changes in effect have been adjusted for baseline differences for each model and are representative of an annual timeframe (see table 2 for 
more details).
‡Not cost-effective is suggested if the effect is negative and therefore the ICER is negative; not cost-effective may also be suggested when 
the ICER is positive due to both a negative cost and effect that is, positioned in the Southwest quadrant of the cost-effectiveness plane, 
depending on the WTP threshold. As the stated WTP threshold is £20 000 per QALY gain, all positive ICERs due to positive costs and effects 
that are over £20 000 are also deemed not cost-effective. Also note that CIs were not reported as the analysis are deterministic and non-
linear; therefore CIs could not be meaningfully interpreted.
§Average unadjusted EQ-VAS scores across baseline to day 7 are presented in the (online supplementary appendix). After adjustments for 
imbalance at baseline, the incremental effect was negative at −0.174 at day 7. The change in effect presented in the table above has been 
adjusted to represent an annual timeframe consistent with cost per QALY interpretation.
EQ-VAS, EuroQol-Visual Analogue Scale; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; WTP, willingness to pay.
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The initial response rate was much lower and a protocol 
amendment which allowed the use of incentives for 
patients who returned diaries was introduced. Reported 
resource use for HSP analysis was cross-checked with a 
follow-up patient survey and medical record review and as 
such where no resource use was identified for each patient 
across the data sources, the assumption of zero resource 
use for that category is justifiable but potentially leading 
to some bias in cost estimates. However, EQ-5D-5L data 
were collected from the patient survey only and missing 
data were considerable at 40%. Although robust multiple 
imputation techniques were applied to impute values, it 
is recognised that the range of covariates used to impute 
missing data may not reflect the degree of heteroge-
neity across the patient cohort and therefore some bias 
may remain in terms of the resource use and outcomes 
reported versus those that were not. If the imputation 
model was mis-specified, the imputation estimates could 
have some degree of bias.31 Due to the high uncertainty 
around observed HRQoL estimates across both arms, 
however, the limitations associated with multiple imputa-
tion are not cause for concern. In the analyses adopting 
a SCP, self-reported data on time unable to engage in 
usual activities and OTC medications purchased were not 
imputed for those with missing data and assumed zero for 
non-responders. The total cost burden to society is more 
than likely underestimated as a result and the SCP cost 
difference across both arms may not be as representative 
as the HCP cost difference.
Further limitations include the interpretation of the 
subgroup analyses given the small sample sizes and 
limitations of the data outlined. The findings based on 
the subgroup analyses should be interpreted with caution 
and need to be assessed with appropriately powered 
trials. However, the subgroup analyses give greater under-
standing of the wide variation in outcomes observed.
Conclusions and policy implications
In conclusion, sore throat has a substantial economic 
burden on healthcare delivery systems with this study 
estimating the economic burden from a HCP in the 
UK at £2.35 billion annually. More effective strategies 
for assessing and providing rapid symptom relief could 
reduce the cost burden as well as improve clinical and 
HRQoL outcomes. The findings of this study suggest 
there is considerable uncertainty in relation to the effec-
tiveness and HRQoL benefit of dexamethasone for sore 
throat and therefore insufficient evidence to suggest 
cost-effectiveness or its adoption as a viable treatment 
strategy. However, there was evidence suggestive of poten-
tial benefits in several subgroups which could be investi-
gated further in follow-up trials.
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